BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 34382277)

  • 1. Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance.
    Lee JW; Kim N; Nam RH; Jang JY; Choi Y; Lee DH
    Helicobacter; 2021 Oct; 26(5):e12844. PubMed ID: 34382277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance.
    Lee JW; Kim N; Nam RH; Lee SM; Kwon YH; Sohn SD; Kim JM; Lee DH; Jung HC
    Helicobacter; 2019 Apr; 24(2):e12561. PubMed ID: 30632237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.
    Wu DC; Hsu PI; Tseng HH; Tsay FW; Lai KH; Kuo CH; Wang SW; Chen A
    Medicine (Baltimore); 2011 May; 90(3):180-185. PubMed ID: 21512411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.
    Kwon YH; Kim N; Lee JY; Choi YJ; Yoon K; Nam RH; Suh JH; Lee JW; Lee DH
    Scand J Gastroenterol; 2016 Mar; 51(3):270-6. PubMed ID: 26452405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
    Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
    Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
    Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
    Fallone CA; Chiba N; van Zanten SV; Fischbach L; Gisbert JP; Hunt RH; Jones NL; Render C; Leontiadis GI; Moayyedi P; Marshall JK
    Gastroenterology; 2016 Jul; 151(1):51-69.e14. PubMed ID: 27102658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
    Almeida N; Romãozinho JM; Donato MM; Luxo C; Cardoso O; Cipriano MA; Marinho C; Sofia C
    Helicobacter; 2014 Apr; 19(2):90-7. PubMed ID: 24506175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-capsule bismuth-based quadruple therapy as a rescue therapy for
    Correia C; Almeida N; Leal C; Branquinho D; Fernandes A; Gravito-Soares E; Calhau C; Bastos I; Vasconcelos H; Figueiredo P
    Scand J Gastroenterol; 2023 Mar; 58(3):227-231. PubMed ID: 36189844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third-line and rescue therapy for refractory
    de Moraes Andrade PV; Monteiro YM; Chehter EZ
    World J Gastroenterol; 2023 Jan; 29(2):390-409. PubMed ID: 36687120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
    Chen Q; Zhang W; Fu Q; Liang X; Liu W; Xiao S; Lu H
    Am J Gastroenterol; 2016 Dec; 111(12):1736-1742. PubMed ID: 27670603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Trends in the Management of Helicobacter pylori Infection in Serbia: Preliminary Results from the European Registry on H. pylori Management.
    Milivojevic V; Babic I; Kekic D; Rankovic I; Sagdati S; Panic N; Spasic IS; Krstic M; Milosavljevic T; Moreira L; Nyssen OP; Mégraud F; O' Morain C; Gisbert J
    Dig Dis; 2023; 41(3):377-386. PubMed ID: 37253341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
    Zhang W; Chen Q; Liang X; Liu W; Xiao S; Graham DY; Lu H
    Gut; 2015 Nov; 64(11):1715-20. PubMed ID: 26338726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
    Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
    Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of triple and quadruple Helicobacter pylori eradication therapies in Iranian children: a randomized clinical trial.
    Bahremand S; Nematollahi LR; Fourutan H; Tirgari F; Nouripour S; Mir E; Aghakhani S
    Eur J Gastroenterol Hepatol; 2006 May; 18(5):511-4. PubMed ID: 16607146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.